New hope for advanced stomach cancer: dual-drug combo enters late-stage trial
NCT ID NCT07332533
First seen Jan 12, 2026 · Last updated May 22, 2026 · Updated 18 times
Summary
This study tests whether a new drug called KN026, combined with chemotherapy and another drug (enlonstobart), works better than the current standard treatment for people with advanced HER2-positive stomach cancer. About 490 adults who have not had prior treatment for their advanced cancer will take part. The goal is to see if the new combination shrinks tumors and helps people live longer without the cancer growing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE GASTRIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.